Paraza Pharma Inc. is pleased to announce a recent publication
Paraza Pharma is happy to announce a joint publication with Epics Therapeutics entitled “Discovery, Optimization, and Preclinical Pharmacology of EP652, a METTL3 Inhibitor with Efficacy in Liquid and Solid Tumor Models.” J. Med. Chem. 2025, ASAP.
Paraza Pharma Strengthens Leadership with the Acquisition of Analytical Services from adMare BioInnovations to Catalyze Growth and Innovation
Montreal, QC – November 28, 2024 – Paraza Pharma, a leading contract research organization (CRO) specializing in end-to-end drug discovery services, is proud to announce the acquisition of adMare BioInnovations’ Analytical Services.
Paraza Lecture Series -Dr. Corey Stephenson, University of British Columbia
As part of our 2024 Paraza Lecture Series, we wish to welcome Dr. Corey Stephenson, University of British Columbia on November 25th, 2024.
Seminar Title: Redox Catalysis Strategies for Complex Molecules
36th EORTC-NCI-AACR conference from Oct. 23rd to 25th, 2024
Paraza is excited to announce that we will be attending the 36th EORTC-NCI-AACR conference at CCIB in Barcelona, Spain from Oct. 23rd to 25th, 2024. We look forward to seeing you at Booth 12.
Paraza Pharma symposium on organic chemistry – Second Edition
Paraza Pharma is excited to invite graduate students and post-docs in the field of organic chemistry to join Paraza scientists for a full day event.
Paraza Pharma is Delighted to Announce the Launch of the Victor Snieckus Foundation Fellowship Program in Chemistry
On June 2nd, 2024, the Victor Snieckus Foundation Fellowship Program in Chemistry was launched. Paraza Pharma proudly stands as the anchor sponsor of this newly formed fellowship program, dedicated to honoring the legacy and passion of Professor Victor Snieckus by championing excellence in synthetic organic chemistry.
Paraza Pharma Presenting the Bernard Belleau Award at 2024 CSC Conference
On June 5th, 2024, Paraza Pharma will have the pleasure of presenting Professor Derek A. Pratt with the Bernard Belleau Award at the 2024 CSC Conference in Winnipeg, Manitoba. This award is given to a Canadian scientist who has made a significant contribution in the field of Medicinal Chemistry.
Paraza Pharma Inc. is pleased to announce a recent publication in the Eur. J.Org. Chem
An article reporting on the synthesis of 2-aryl-pyrido[2,3-b]pyrazines was published in the journal Eur. J. Org Chem. These results stem from the work of co-op students Tess Fortier, Frédéric Vuillermet, and Joanick Bourret along with Audrey Belouin and Guillaume Pelletier which are linked to our co-op program.
Paraza Lecture Series -Dr. Richmond Sarpong, University of California Berkeley
As part of our 2024 Paraza Lecture Series, we wish to welcome Dr. Richmond Sarpong, University of California Berkeley on April 4th, 2024.
Seminar Title: Break-it-to-Make-it Strategies for Chemical Synthesis Inspired by Complex Natural Products
Paraza Pharma Inc. is pleased to announce a recent publication
A paper disclosing the discovery of TRPA1 receptor antagonist GDC-6599, a potential first-in-class therapy for respiratory diseases has just been published in the Journal of Medicinal Chemistry. This work was conducted in collaboration with Genentech.